"Recruiting patients to participate in clinical trials can be a significant pain point for pharmaceutical companies and can cause costly delays in their drug development processes," said Al Heller, an operating partner with Water Street who has more than 30 years of pharmaceutical experience. "CCBR-SYNARC stands out for its proven ability to both quickly recruit patients from targeted geographies and efficiently analyze images to support customers while increasing their clinical trial success rates."CCBR-SYNARC expands Water Street's group of companies specializing in health care products and services to 12. The firm is also an investor in AAIPharma Services Corp., a provider of pharmaceutical product development services. It sold its oral health pharmaceutical company, OraPharma, to Valeant Pharmaceuticals International, Inc. last year. Since its founding in 2005, Water Street has completed 39 transactions to create and grow a diverse group of market-leading health care companies.
Water Street Invests In Global Pharmaceutical Services Company
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.